ArticleNanoscale2018
Stimuli-responsive lipid-based magnetic nanovectors increase apoptosis in glioblastoma cells through synergic intracellular hyperthermia and chemotherapy.
Article in Nanoscale, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 92 citations in OpenAlex.
- Magnetic field-guided enhancement of nanoparticle uptake and hyperthermia efficacy in 3D tumour models.Nanoscale advances · 2026Article
- Dual-Function Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization.Drug development research · 2026Review
- A Theoretical Framework for Ligand-Functionalised Magnetic Lipid Nanoparticles in Glioblastoma Therapy.Cancers · 2025Review
- Thermo-Magnetic Induction of Pro-Inflammatory Microglia: A Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy.ACS applied materials & interfaces · 2025Article
- Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.Therapeutic delivery · 2025Review
- Nanoplatforms for Magnetic-Photo-Heating of Thermo-Resistant Tumor Cells: Singular Synergic Therapeutic Effects at Mild Temperature.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Remotely Controlled 3D-Engineered Scaffolds for Biomimetic In Vitro Investigations on Brain Cell Cocultures.Advanced intelligent systems (Weinheim an der Bergstrasse, Germany) · 2024Article
- Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology.Pharmaceuticals (Basel, Switzerland) · 2024Review
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme.ACS nano · 2023Article
- Cell-Membrane-Coated and Cell-Penetrating Peptide-Conjugated Trimagnetic Nanoparticles for Targeted Magnetic Hyperthermia of Prostate Cancer Cells.ACS applied materials & interfaces · 2023Article
- Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation.Pharmaceutics · 2023Article
- Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).Cancers · 2023Review
- How Magnetic Composites are Effective Anticancer Therapeutics? A Comprehensive Review of the Literature.International journal of nanomedicine · 2023Review
- Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery.Research (Washington, D.C.) · 2023Review
- Insights into the Effect of Magnetic Confinement on the Performance of Magnetic Nanocomposites in Magnetic Hyperthermia and Magnetic Resonance Imaging.ACS applied nano materials · 2022Article
- Ferroptosis and Its Potential Role in Glioma: From Molecular Mechanisms to Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2022Review
- Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?Cancers · 2022Review
- Article
- Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment-An Update.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
In this study, taking into consideration the limitations of current treatments of glioblastoma multiforme, we fabricated a biomimetic lipid-based magnetic nanovector with a good loading capacity and a sustained release profile of the encapsulated chemotherapeutic drug, temozolomide. These nanostructures demonstrated an enhanced release after exposure to an alternating magnetic field, and a complete release of the encapsulated drug after the synergic effect of low pH (4.5), increased concentration of hydrogen peroxide (50 μM), and increased temperature due to the applied magnetic field. In addition, these nanovectors presented excellent specific absorption rate values (up to 1345 W g-1) considering the size of the magnetic component, rendering them suitable as potential hyperthermia agents. The presented nanovectors were progressively internalized in U-87 MG cells and in their acidic compartments (i.e., lysosomes and late endosomes) without affecting the viability of the cells, and their ability to cross the blood-brain barrier was preliminarily investigated using an in vitro brain endothelial cell-model. When stimulated with alternating magnetic fields (20 mT, 750 kHz), the nanovectors demonstrated their ability to induce mild hyperthermia (43 °C) and strong anticancer effects against U-87 MG cells (scarce survival of cells characterized by low proliferation rates and high apoptosis levels). The optimal anticancer effects resulted from the synergic combination of hyperthermia chronic stimulation and the controlled temozolomide release, highlighting the potential of the proposed drug-loaded lipid magnetic nanovectors for treatment of glioblastoma multiforme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.